How Strattera Works: Mechanism, Dosage, and Precautions

Key Takeaways

• Strattera (atomoxetine) is an FDA-approved non-stimulant attention-deficit/hyperactivity disorder (ADHD) medication that increases norepinephrine activity to help improve focus and impulse control.
• Unlike stimulant ADHD medications, Strattera is not a controlled substance and usually requires several weeks of consistent use before full benefits appear.
• Prescribers adjust Strattera dosage based on body weight or standard titration schedules while monitoring side effects such as appetite loss, blood pressure changes, and mood symptoms.

Strattera is the first non-stimulant medication to earn FDA approval specifically for attention-deficit hyperactivity disorder (ADHD), which was cleared for use in 2002. If you or your child has been prescribed it, or you're weighing treatment options, knowing how it actually works in the brain changes the conversation.

ADHD affects far more people than many realize. A 2023 rapid survey analysis published in the Centers for Disease Control and Prevention's (CDC) Morbidity and Mortality Weekly Report (MMWR) estimated that roughly 15.5 million U.S. adults have an ADHD diagnosis, and about one-third aren't receiving any treatment.

Understanding the Strattera medication dosing schedule and its safety considerations helps you have a more productive conversation with your prescriber.

What is Strattera and How Does it Work?

Strattera is the brand name for atomoxetine, an FDA-approved selective norepinephrine reuptake inhibitor (SNRI) that operates through a fundamentally different mechanism than stimulant ADHD medications on the market.

While stimulants fill the brain with dopamine relatively quickly and broadly, atomoxetine works selectively and more gradually. Atomoxetine works by blocking the norepinephrine transporter (NET), raising norepinephrine and dopamine in the prefrontal cortex.

The prefrontal cortex is the area of the brain governing attention, working memory, and impulse control. Because it doesn't significantly raise dopamine in the brain's reward center, it has low abuse potential and isn't classified as a controlled substance under ther U.S. law.

Strattera's targeted action also impacts how long it takes to work. A review in the Journal of Psychopharmacology found that early improvements may appear within 1–2 weeks in eventual responders, but clinically meaningful change typically takes 4–6 weeks. However, full therapeutic benefit often requires 8–12 continuous weeks of use at the right dose.

Learning more about ADHD can help set realistic expectations for what any treatment can achieve over time.

How Effective is Strattera for ADHD?

Strattera can reduce ADHD symptoms across age groups, with response rates that hold up in both short-term and long-term trials.

In a 24-week randomized controlled trial (RCT) in adults, once-daily atomoxetine produced a 68% response rate (defined as a 25% or higher reduction in symptoms) versus 42% for placebo, based on results published in the Clinical Neuropharmacology Journal.

In children, a study in the Journal of the American Academy of Child and Adolescent Psychiatry found that 44.4% achieved meaningful symptom reduction compared to 21.4% on placebo. Effectiveness also holds across pediatric age ranges. A meta-analysis in the Child and Adolescent Psychiatry and Mental Health found response rates of 55.7% in children ages 6–7 and 63.5% in those ages 8–12, both significantly outpacing placebo.

A practical advantage worth noting is how long Strattera is effective. The pediatric RCT in Clinical Neuropharmacology confirmed that once-daily morning dosing produced measurable ADHD symptom benefits through evenings and into the following morning across eight weeks. For families managing school, homework, and bedtime routines, that around-the-clock effect has real-life value.

What is the Recommended Strattera Dosage?

Strattera medication comes in a range of dosages, including capsules of 10, 18, 25, 40, 60, 80, and 100 mg. A prescriber sets the starting dose based on body weight in children or a fixed schedule in adults. Regardless of age, the capsules must be swallowed whole, as opening, crushing, or chewing them can irritate mucous membranes.

Adult dosing schedule

Adults and adolescents weighing more than 70 kg (154 pounds) follow a three-phase dose adjustment (called titration), as outlined by the National Library of Medicine in the following table.

Daily dose doesn't exceed 100 mg, because there is no additional benefit of going above this amount. A person can take a single dose in the morning or split the dose between morning and late afternoon or evening.

Pediatric dosing

For children and adolescents at or under 70 kg (154 pounds), dosing is weight-based:

• Starting dose: 0.5 mg/kg/day
• Target dose: 1.2 mg/kg/day after a minimum of 3 days
• Maximum dose: 1.4 mg/kg/day or 100 mg, whichever is lower

A dose-response meta-analysis of 12 RCTs in the Journal of Attention Disorders confirmed that efficacy plateaus at approximately 1.4 mg/kg/day, meaning higher doses add side effect risk without adding benefit. Children and adolescents over 70 kg (154 pounds) follow the adult titration schedule.

Administration and titration tips

A few practical adjustments can improve tolerability throughout the titration process, including:

• Taking atomoxetine at the same time each day to maintain steady blood levels
• If nausea occurs, taking it with food usually helps
• Taking missed doses as soon as remembered, but skipping a missed dose if the next scheduled dose is near (never double up)

According to a book published by StatPearls, about 7% of Caucasians metabolize CYP2D6 poorly, meaning atomoxetine stays in their system much longer. Atomoxetine may stay in their systems up to about 24 hours, versus around five hours in a person with typical metabolization.

Strong CYP2D6 inhibitors, including fluoxetine, paroxetine, and quinidine, can more than double atomoxetine plasma levels. In these cases, the FDA label caps the daily maximum at 80 mg.

Precautions and Contraindications for Taking Strattera

Strattera isn't the right fit for everyone, and certain medical histories require either close monitoring or full avoidance. Situations in which you should not take Strattera include:

• Current use of monoamine oxidase inhibitors (MAOIs), or use within the past 14 days
• Narrow-angle glaucoma
• A history of pheochromocytoma or paraganglioma
• Severe cardiovascular conditions where increases in blood pressure or heart rate could cause harm

Before and during treatment, providers typically monitor blood pressure and heart rate. For children, they also monitor height and weight. Any new or worsening psychiatric symptoms, signs of liver problems such as jaundice or dark urine, or thoughts of self-harm require immediate medical attention.

What Side Effects and Drug Interactions are Common with Strattera?

Starting a new mental health medication often raises questions about benefits and possible side effects. With Strattera medication, most people encounter manageable GI or sleep-related symptoms, especially early in treatment. Serious effects are less common but important to recognize quickly.

Common side effects

The most frequently reported adverse effects in adult and pediatric trials appear in the table below.

A pediatric meta-analysis in Psychopharmacology (Berlin) found that decreased appetite carried the highest risk among children.

Splitting the total daily dose into morning and afternoon portions may reduce both GI discomfort and appetite effects for some individuals.

Serious side effects: When to call a doctor

Less common reactions warrant prompt medical evaluation, including the following:

• Suicidal thoughts: The FDA carries a boxed warning after short-term trials found a 0.4% rate of suicidal thoughts in children and adolescents on atomoxetine versus 0% on placebo.
• Liver injury: LiverTox estimates aminotransferase elevations in approximately 0.5% of patients, with rare acute injury to liver cells typically appearing 3–12 weeks after starting treatment.
• Cardiovascular effects: Clinically significant diastolic blood pressure rises (15 mmHg or higher) occur in 5–9% of adults, with systolic hypertension in about 4–5%.
• Priapism: Prolonged or painful erections require immediate evaluation.

Key drug interactions

Drug interactions are serious, so it's important to talk to your care provider about what medications you currently take or have taken in the past. Three interaction categories carry the greatest clinical significance, as outlined below:

How Does Strattera Compare with Stimulant Medications?

For someone newly diagnosed with ADHD, the choice between Strattera and a stimulant often shapes how the first months of treatment feel. Their mechanisms, timelines, and practical profiles differ in ways that matter to real people making real decisions.

The following table provides a comparison of Strattera with stimulant ADHD medications:

According to a 2025 systematic review in the Frontiers in Child and Adolescent Psychiatry, methylphenidate showed modest benefits in certain behavioral areas, with 62% of children maintaining improvement after one year compared to 54% on other treatments, but overall, it wasn't clearly more effective.

Strattera is typically chosen when stimulants aren't tolerated, aren't appropriate given a substance use history, or haven't produced adequate results.

A deeper look at stimulant vs non-stimulant ADHD medications can help you and your care provider formulate the approach that fits your specific situation.

Support for ADHD and Medication-Related Stress

Starting Strattera often brings up more than just questions about dosing. It can take several weeks before the full effects appear, and during that time, you may notice mood changes, shifts in appetite, or uncertainty about whether the medication is working.

These experiences are real, and they're exactly the kinds of challenges that therapy is built to address.

Talkspace connects you with licensed therapists who understand both ADHD treatment and the emotional complexity of managing a new treatment plan. Sessions are available via video, audio, and message-based therapy, so consistent support is accessible around your schedule, and not the other way around.

Therapy doesn't replace your prescriber's role. What it does is give you space to process what's happening between appointments, build coping strategies, and feel less alone in what can be a slow and sometimes frustrating process. When medication and mental health care work together, you tend to get more out of both.

Explore Talkspace's online treatment options for ADHD and connect with a licensed therapist who can support you through every stage of care.

Frequently Asked Questions (FAQs)

How long does it take for Strattera to start working?

Strattera (atomoxetine) does not work immediately like some other medications. It usually takes 4 to 6 weeks to notice a significant improvement in symptoms, and the full effect may take up to 8 weeks. Taking it consistently every day is important, and your doctor may adjust the dose during this period.

Can I take Strattera at night?

Yes, Strattera can be taken at night, but it’s recommended to take it at the same time every day. Some people may experience insomnia or sleep disturbances, so if that happens, taking it in the morning might be better. Always follow your prescribing doctor’s advice.

Does Strattera cause weight loss or gain?

Strattera can affect weight, but the impact varies between people. Some individuals may experience slight weight loss, often due to reduced appetite, while others may have minimal or no change. Significant weight gain is less common.

Will Strattera show up on a drug test?

Strattera is not a controlled substance and is not typically detected on standard drug tests. It generally does not cause a positive result, so routine screenings should not be affected.

What should I do if I miss a Strattera dose?

If you miss a dose of Strattera, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and do not take a double dose. It is important to take Strattera at the same time every day to maintain consistent effects.

Sources:

1. Staley BS, Robinson, LR, Claussen AH, et al. Attention-deficit/hyperactivity disorder diagnosis, treatment, and telehealth use in adults — National Center for Health Statistics rapid surveys system, United States, October–November 2023. Morbidity and Mortality Weekly Report. https://www.cdc.gov/mmwr/volumes/73/wr/mm7340a1.htm. 2024 Oct 10; 73(40):873-879. Accessed March 3, 2026.
2. Bushe CJ and Savill NC. Systematic review of atomoxetine data in childhood and adolescent attention-deficit hyperactivity disorder 2009–2011: focus on clinical efficacy and safety. Journal of Psychopharmacology. https://pubmed.ncbi.nlm.nih.gov/23438503/. 2014 March;28(3):204-11. Accessed March 3, 2026.
3. Young JL, Sarkis E, Qiao M, Wietecha L. Once-daily treatment with atomoxetine in adults with attention-deficit/hyperactivity disorder: a 24-week, randomized, double-blind, placebo-controlled trial. Clinical Neuropharmacology. https://pubmed.ncbi.nlm.nih.gov/21406998/. 2011 Mar-Apr;34(2):51-60. Accessed March 3, 2026.
4. Schwartz S and Correl CU. Efficacy and safety of atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: results from a comprehensive meta-analysis and metaregression. Journal of the American Academy of Child and Adolescent Psychiatry. https://pubmed.ncbi.nlm.nih.gov/24472252/. 2014 Feb;53(2):174-187. Accessed March 3, 2026.
5. Kratochvil CJ, Milton DR, Vaughan BS and Greenhill LL. Acute atomoxetine treatment of younger and older children with ADHD: A meta-analysis of tolerability and efficacy. Child and Adolescent Psychiatry and Mental Health. https://pmc.ncbi.nlm.nih.gov/articles/PMC2556311/. 2008 Sep;15;2:25. Accessed March 3, 2026.
6. DailyMed. STRATTERA – atomoxetine hydrochloride capsule. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=309de576-c318-404a-bc15-660c2b1876fb. Updated 2025 Dec 31. Accessed March 3, 2026.
7. Terao I, Kodama W and Tsuda H. The dose-response relationship of atomoxetine for the treatment of children with ADHD: a systematic review and dose-response meta-analysis of double-blind randomized placebo-controlled trials. Journal of Attention Disorders. https://pubmed.ncbi.nlm.nih.gov/38069471/. 2024 Feb;28(4):431-438. Accessed March 3, 2026.
8. Fedder D, Patel H and Saadabadi A. Atomoxetine. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK493234/. Updated 2023 March 27. Accessed March 3, 2026.
9. Cheng JYW, Chen RYL, Ko JSN and Ng EML. Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents: meta-analysis and meta-regression analysis. Psychopharmacology (Berlin). https://pubmed.ncbi.nlm.nih.gov/17572882/. 2007 Oct;194(2):197-209. Accessed March 3, 2026.
10. National Institute of Diabetes and Digestive and Kidney Diseases. Atomoxetine. LiverTox. https://www.ncbi.nlm.nih.gov/books/NBK548671/. Updated 2021 Aug 25. Accessed March 3, 2026.
11. Oliveira HF, et al. Efficacy and safety of atomoxetine in the treatment of ADHD in children and adolescents: a systematic review. Frontiers in Child and Adolescent Psychiatry. https://www.frontiersin.org/journals/child-and-adolescent-psychiatry/articles/10.3389/frcha.2025.1731330/full. 2026 Jan 5;(4). Accessed March 3, 2026.

Talkspace articles are written by experienced mental health-wellness contributors; they are grounded in scientific research and evidence-based practices. Articles are extensively reviewed by our team of clinical experts (therapists and psychiatrists of various specialties) to ensure content is accurate and on par with current industry standards.

Our goal at Talkspace is to provide the most up-to-date, valuable, and objective information on mental health-related topics in order to help readers make informed decisions. Articles contain trusted third-party sources that are either directly linked to in the text or listed at the bottom to take readers directly to the source.